Insulet Corporation

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods

NEW YORK, March 25, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin leakage -- a defect linked to eighteen serious adverse events. Shareholders who lost money on their PODD investment are encouraged to submit their information here . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The voluntary correction disclosed that the affected pods -- representing roughly 1.5% of annual production -- carried a defect capable of causing insulin leakage leading to hospitalization and diabetic ketoacidosis (DKA). Levi & Korsinsky is investigating whether Insulet and certain executives were aware of the defect prior to the March 12 disclosure, including during the Company's Q4 2025 earnings call on February 18, 2026, where CEO Ashley McEvoy described Omnipod as demonstrating "reliability, consistency and broad appeal" and stated that "real-world outcomes continue to earn prescriber and patient confidence."

The 8-K filing referenced eighteen serious adverse events tied to the defect. The FDA's medical device correction database catalogued the action. No serious adverse events had been referenced in the February 18 prior filing or earnings presentation.

If you purchased Insulet Corp. shares and suffered a loss, click here to discuss your legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/podd-investor-alert-insulet-corp-potential-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-concealed-device-defect-levi--korsinsky-302724414.html

SOURCE Levi & Korsinsky, LLP

Insulet CEO Called Omnipod 5 "Reliable" and a "Favorite Pump" on February 18 -- Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective Pods

NEW YORK, March 18, 2026 /PRNewswire/ -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that "our results in the fourth quarter are a testament to the reliability, consistency and broad appeal of Omnipod." On March 12, 2026, the Company filed an 8-K disclosing a voluntary medical-device correction for Omnipod 5 pods due to an insulin-leakage defect linked to eighteen serious adverse events -- and PODD shares fell 6.9%. Shareholders who lost money on PODD are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.

Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.

If you purchased Insulet Corp. shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/podd-investor-alert-insulet-corp-potential-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-executives-allegedly-misled-on-safety-levi--korsinsky-302717924.html

SOURCE Levi & Korsinsky